Statistical analysis
infection
ADVERSE EVENTS, INFECTION, SARS-COV-2 INFECTION
Based on our preliminary data, assuming a GMT of 27 with an SD of logFor vaccine immunogenicity (primary outcome), we included data from all participants who received the assigned vaccination and provided days 0 and 28 sera samples in our trial (ie, per-protocol analysis). For adverse events, we included all available data. For SARS-CoV-2 infection, we included data from participants who agreed to participate in active surveillance and had reported at least once self-administered rapid antigen test result from the systematic monitoring, and had also reported information on any infection that occurred before active surveillance started.For SARS-CoV-2 serum neutralising antibody PRNTWe conducted complete case analyses for reactogenicity and incidence of SARS-CoV-2 infection. Rates of solicited local and systemic adverse events or symptoms were compared between study groups using Pearson’s χA data monitoring committee was deemed unnecessary because both vaccines had obtained emergency use approval in the community. The study is registered in 